
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
about 7 years ago
What’s New in Regulations and Complianceabout 7 years ago
Quality Culture Drives Patient Confidence in Drug Productsabout 7 years ago
Generics: Getting Beyond “File First, Figure it Out Later”about 7 years ago
Global Pharmacopoeia Standards: Why Harmonization is Needed (eBook)about 7 years ago
Why Pharmacopoeia Compliance Is Difficult (eBook)about 7 years ago
Why Pharmacopoeia Compliance Is Necessary (eBook)about 7 years ago
Resources, Guidelines, and Guidance Documents





